Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 7/20 | 0.49 |
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | DRD1 | P21728 | 11/20 | 0.49 |
| ▸ | DRD2 | P14416 | 10/20 | 0.49 |
| ▸ | DRD5 | P21918 | 9/20 | 0.49 |
| ▸ | DRD3 | P35462 | 8/20 | 0.49 |
| ▸ | DRD4 | P21917 | 6/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799659 | 0.93 | DRD2 (0.45) | ESR2ESR1DRD1DRD2DRD5 | |
| SCHEMBL6801258 | 0.87 | DRD1 (0.47) | ESR2ESR1DRD1DRD2DRD5 | |
| SCHEMBL6799175 | 0.87 | DRD1 (0.47) | ESR2ESR1DRD1DRD2DRD5 | |
| SCHEMBL6797459 | 0.79 | DRD2 (0.43) | ESR2ESR1DRD1DRD2DRD5 | |
| SCHEMBL21326866 | 0.79 | DRD2 (0.40) | ESR2ESR1DRD1DRD2DRD5 | |
| SCHEMBL6796118 | 0.79 | ESR1 (0.42) | ESR2ESR1DRD1DRD2DRD5 | |
| SCHEMBL196204 | 0.78 | SIGMAR1 (0.44) | DRD1DRD2DRD5DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL21326854 | 0.78 | ESR1 (0.39) | ESR2ESR1DRD1DRD2DRD5 | |
| Bromide SCHEMBL21326962 | 0.78 | ESR1 (0.39) | ESR2ESR1DRD1DRD2DRD5 | |
| SCHEMBL3778634 | 0.77 | SIGMAR1 (0.62) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | MERCK & CO., INC. | 2004-04-29 | — | — | US | disclosed |
| EP-1339662-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002046134-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS AND METHODS III | KARO BIO AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082642-A1 | Novel estrogen receptor ligands and method III | ESRRA, ESRRB, FSHR | ESR2 5/4885ESR1 19/4885DRD1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.